CureVac (CVAC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CureVac’s partner GSK has reported positive Phase 2 results from their seasonal influenza mRNA vaccine program, demonstrating strong immune responses and an acceptable safety profile. The vaccine, utilizing CureVac’s second-generation mRNA technology, is slated for Phase 3 trials, marking a significant milestone for CureVac. These developments could potentially enhance CureVac’s market position and offer new solutions for influenza prevention.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
